2. Search Result
Search Result
Results for "

RGDS

" in MedChemExpress (MCE) Product Catalog:

54

Inhibitors & Agonists

1

Fluorescent Dye

42

Peptides

1

Inhibitory Antibodies

3

Natural
Products

3

Oligonucleotides

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-12290
    Arg-Gly-Asp-Ser
    Maximum Cited Publications
    6 Publications Verification

    RGDS peptide; Fibronectin tetrapeptide

    		 Integrin Inflammation/Immunology
    Arg-Gly-Asp-Ser is an integrin binding sequence that inhibits integrin receptor function. Arg-Gly-Asp-Ser directly and specifically bind pro-caspase-8, pro-caspase-9 and pro-caspase-3, while it does not bind pro-caspase-1.
    Arg-Gly-Asp-Ser
  • HY-P2219A
    CGGRGD TFA

    		Amino Acid Derivatives Cancer
    CGGRGD TFA, a RGD derivative with cysteine as its N-terminal .
    CGGRGD TFA
  • HY-134130
    Integrin modulator 1

    		Integrin Inflammation/Immunology
    Integrin modulator 1 is a potent and selective α4β1 integrin agonist, with an IC50 of 9.8 nM for RGD-binding α4β1. Integrin modulator 1 increases cell adhesion mediated by α4β1 integrin, with an EC50 of 12.9 nM .
    Integrin modulator 1
  • HY-P5021
    Cyclo(Arg-Gly-Asp-(D-Phe)-Glu)

    c(RGDfE)

    		 Biochemical Assay Reagents Cancer
    Cyclo(Arg-Gly-Asp-(D-Phe)-Glu) (c(RGDfE)) is a cyclic RGD peptide that serves as a conjugated multifunctional nanodrug delivery system to target Gemcitabine to pancreatic cancer cells. Cyclo(Arg-Gly-Asp-(D-Phe)-Glu) can be used in cancer research .
    Cyclo(Arg-Gly-Asp-(D-Phe)-Glu)
  • HY-12290A
    Arg-Gly-Asp-Ser TFA

    RGDS peptide TFA; Fibronectin tetrapeptide TFA

    		 Integrin Inflammation/Immunology
    Arg-Gly-Asp-Ser (TFA) is an integrin binding sequence that inhibits integrin receptor function. Arg-Gly-Asp-Ser (TFA) directly and specifically bind pro-caspase-8, pro-caspase-9 and pro-caspase-3, while it does not bind pro-caspase-1 .
    Arg-Gly-Asp-Ser TFA
  • HY-P2635
    RGDSPASSKP

    		Integrin Cancer
    RGDSPASSKP is a RGDS-containing fibronectin decapeptide .
    RGDSPASSKP
  • HY-P2219
    CGGRGD

    		Amino Acid Derivatives Cancer
    CGGRGD, a RGD derivative with cysteine as its N-terminal .
    CGGRGD
  • HY-P1702
    GR83895

    		Integrin Others
    GR83895 is a RGD based peptide, and inhibits ADP-induced platelet aggregation of human gel-filtered platelets (IC50= 0.9 μM) .
    GR83895
  • HY-D2439
    RGD-PEG-Cy3

    		Fluorescent Dye Cancer
    RGD-PEG-Cy3 is a fluorescent labeling reagent that combines Cy3 fluorescent dye, peptide (RGD) and polyethylene glycol (PEG). The Cy3 fluorophore is commonly used in applications such as immunolabeling, nucleic acid labeling, fluorescence microscopy, and flow cytometry. Cy3 has an emission maximum around 562-570 nm. RGD is a peptide sequence (CRGDKGPDCiRGD) that binds to αvβ3 and αvβ5 integrin receptors on tumor neovasculogenesis to achieve specific tumor tissue targeting .
    RGD-PEG-Cy3
  • HY-P3530
    G-{d-Arg}-GDSP

    		Integrin Others
    G-{d-Arg}-GDSP is an RGD peptide analogue that binds to the adhesion receptor of integrins and inhibits cellular fibronectin attachment as well as osteoclast resorption .
    G-{d-Arg}-GDSP
  • HY-P1408
    Obtustatin

    		Integrin Cancer
    Obtustatin is a non-RGD disintegrin of 41 residues. Obtustatin can be isolated from Vipera lebetina obtusa venom. Obtustatin is a potent and selective inhibitor of the adhesion of integrin α1β1 to collagen IV. Obtustatin inhibits angiogenesis, and can be used for research of cancer .
    Obtustatin
  • HY-P0322
    GRGDSPK

    EMD 56574

    		 Integrin Cardiovascular Disease Metabolic Disease
    GRGDSPK (EMD 56574) is a peptide incluing Arg-Gly-Asp (RGD). GRGDSPK (EMD 56574) is an competitive and reversible inhibitory peptide for inhibiting integrin-fibronectin binding. GRGDSPK is used to study the role of integrins in bone formation and resorption .
    GRGDSPK
  • HY-P0322A
    GRGDSPK TFA

    EMD 56574 TFA

    		 Integrin Cardiovascular Disease Metabolic Disease
    GRGDSPK TFA (EMD 56574 TFA) is a peptide incluing Arg-Gly-Asp (RGD). GRGDSPK TFA is an competitive and reversible inhibitory peptide for inhibiting integrin-fibronectin binding. GRGDSPK TFA is used to study the role of integrins in bone formation and resorption .
    GRGDSPK TFA
  • HY-P4907
    RGD Negative Control

    		Integrin Others
    RGD Negative Control is the negative control of RGD (HY-P0278).
    RGD Negative Control
  • HY-P3732
    RGD-4C

    		Integrin Cancer
    RGD-4C is a arginine-glycine-aspartic acid peptide (ACDCRGDCFC) with integrin binding activity. The Arg-Gly-Asp (RGD) sequence serves as the primary integrin recognition site in extracellular matrix proteins, and peptides containing this sequence can mimic the recognition specificity of the matrix proteins. RGD-4C is a αv-integrin ligand, can conjugate with bioactive molecule to exert antitumor effects in animal models .
    RGD-4C
  • HY-P5053
    Galacto-RGD

    		Radionuclide-Drug Conjugates (RDCs) Integrin Cancer
    Galacto-RGD is an RGD analogue that can be coupled with the radioactive isotope 18F and used as an integrin α?β? selective tracer . Galacto-RGD can be used for the synthesis/research of Radionuclide-Drug Conjugates (RDCs).
    Galacto-RGD
  • HY-RS25049
    Ralgds Rat Pre-designed siRNA Set A

    		Small Interfering RNA (siRNA) Others

    Ralgds Rat Pre-designed siRNA Set A contains three designed siRNAs for Ralgds gene (Rat), as well as a negative control, a positive control, and a FAM-labeled negative control.

    Ralgds Rat Pre-designed siRNA Set A
    Ralgds Rat Pre-designed siRNA Set A
  • HY-P0278A
    RGD Trifluoroacetate
    Maximum Cited Publications
    6 Publications Verification

    		 Integrin Cancer
    RGD Trifluoroacetate is a tripeptide that effectively triggers cell adhesion, addresses certain cell lines and elicits specific cell responses; RGD Trifluoroacetate binds to integrins.
    RGD Trifluoroacetate
  • HY-P1740
    RGD peptide (GRGDNP)
    5 Publications Verification

    		 Integrin Apoptosis Caspase Inflammation/Immunology
    RGD peptide (GRGDNP) is an inhibitor of integrin-ligand interactions. RGD peptide (GRGDNP) competitively inhibits α5β1 binding with extracellular matrice (ECM). RGD peptide (GRGDNP) promotes apoptosis through activation of conformation changes that enhance pro-caspase-3 activation and autoprocessing. RGD peptide (GRGDNP) plays an important role in cell adhesion, migration, growth, and differentiation .
    RGD peptide (GRGDNP)
  • HY-P1740A
    RGD peptide (GRGDNP) (TFA)
    5 Publications Verification

    		 Integrin Apoptosis Inflammation/Immunology Cancer
    RGD peptide (GRGDNP) TFA is an inhibitor of integrin-ligand interactions. RGD peptide (GRGDNP) TFA competitively inhibits α5β1 binding with extracellular matrice (ECM). RGD peptide (GRGDNP) TFA promotes apoptosis through activation of conformation changes that enhance pro-caspase-3 activation and autoprocessing. RGD peptide (GRGDNP) TFA plays an important role in cell adhesion, migration, growth, and differentiation .
    RGD peptide (GRGDNP) (TFA)
  • HY-176300
    RGD-DA6

    		Integrin Cancer
    RGD-DA6 is an αvβ3-targeted ligand. RGD-DA6 consists of RGDfK (an integrin αvβ3-targeted RGD peptide), DOTADG, d-Glu, Lys, AMBA, and IPBA. RGD-DA6 can be radiolabeled as an αvβ3-targeted radioligand and used for high-contrast tumor imaging and enhanced anticancer efficacy .
    RGD-DA6
  • HY-P0290
    GRGDSP
    5 Publications Verification

    		 Integrin Cancer
    GRGDSP, a synthetic linear RGD peptide, is an integrin inhibitor.
    GRGDSP
  • HY-157157
    PAD4-IN-3

    		Protein Arginine Deiminase Cancer
    PAD4-IN-3 (compound 4B) is a PAD4 inhibitor with antitumor activity in vitro and in vivo. PAD4-IN-3 was covalently linked to RGD sequence peptide-modified chitosan (K-CRGDV), resulting in an enhanced oxidative stress-responsive nanoagent. K-CRGDV-PAD4-IN-3 can actively target tumors, inhibit PAD4 activity, block the formation of neutrophil extracellular traps (NETs), and improve the tumor immune microenvironment in response to the tumor microenvironment .
    PAD4-IN-3
  • HY-P0278
    RGD
    Maximum Cited Publications
    6 Publications Verification

    		 Integrin Cancer
    RGD is a tripeptide that effectively triggers cell adhesion, addresses certain cell lines and elicits specific cell responses; binds to integrins.
    RGD
  • HY-P0309
    Arg-Gly-Glu-Ser

    		Integrin Cancer
    Arg-Gly-Glu-Ser is a polypeptide related to RGD and is a negative control for Arg-Gly-Asp-Ser (HY-12290) .
    Arg-Gly-Glu-Ser
  • HY-P3227
    Cyclo(Ala-Arg-Gly-Asp-Mamb)

    XJ735

    		 Integrin Inflammation/Immunology
    Cyclo(Ala-Arg-Gly-Asp-Mamb) is a selective RGD peptide antagonist and has the potential for Pulmonary arterial hypertension Research .
    Cyclo(Ala-Arg-Gly-Asp-Mamb)
  • HY-P0309A
    Arg-Gly-Glu-Ser TFA

    		Integrin Inflammation/Immunology
    Arg-Gly-Glu-Ser TFA is a polypeptide related to RGD and is a negative control for Arg-Gly-Asp-Ser (HY-12290) .
    Arg-Gly-Glu-Ser TFA
  • HY-RS18566
    Ralgds Mouse Pre-designed siRNA Set A

    		Small Interfering RNA (siRNA) Others

    Ralgds Mouse Pre-designed siRNA Set A contains three designed siRNAs for Ralgds gene (Mouse), as well as a negative control, a positive control, and a FAM-labeled negative control.

    Ralgds Mouse Pre-designed siRNA Set A
    Ralgds Mouse Pre-designed siRNA Set A
  • HY-RS11633
    RALGDS Human Pre-designed siRNA Set A

    		Small Interfering RNA (siRNA) Others

    RALGDS Human Pre-designed siRNA Set A contains three designed siRNAs for RALGDS gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

    RALGDS Human Pre-designed siRNA Set A
    RALGDS Human Pre-designed siRNA Set A
  • HY-161730
    αvβ1 integrin-IN-3

    		Integrin Cardiovascular Disease Cancer
    αvβ1 integrin-IN-3 is a selective αvβ1 integrin inhibitor. αvβ1 integrin-IN-3 has an antifibrotic effect .
    αvβ1 integrin-IN-3
  • HY-P10941
    VSLRGDTRG

    		Integrin FAK ERK Inflammation/Immunology Cancer
    VSLRGDTRG is a synthetic peptide containing the RGD motif from cadherin 17 (CDH17), which binds to α2β1 integrin and activates its signaling pathway. VSLRGDTRG promotes the high-affinity conformational change of β1 integrin through the RGD motif, enhancing cell adhesion and phosphorylation of FAK and ERK1/2, thereby driving tumor proliferation and metastasis. VSLRGDTRG can be used in research on cancers expressing CDH17, such as colon cancer and pancreatic cancer .
    VSLRGDTRG
  • HY-P10941A
    VSLRGDTRG acetate

    		Integrin FAK ERK Inflammation/Immunology Cancer
    VSLRGDTRG acetate is a synthetic peptide containing the RGD motif from cadherin 17 (CDH17), which binds to α2β1 integrin and activates its signaling pathway. VSLRGDTRG acetate promotes the high-affinity conformational change of β1 integrin through the RGD motif, enhancing cell adhesion and phosphorylation of FAK and ERK1/2, thereby driving tumor proliferation and metastasis. VSLRGDTRG acetate can be used in research on cancers expressing CDH17, such as colon cancer and pancreatic cancer .
    VSLRGDTRG acetate
  • HY-P1930A
    Risuteganib hydrochloride

    		Integrin Inflammation/Immunology
    Risuteganib hydrochloride is a synthetic RGD (arginyl-glycyl-aspartic acid)-class peptide. Risuteganib hydrochloride is an anti-integrin that downregulates oxidative stress and restores homeostasis, and targets three integrin receptors that are implicated in dry age-related macular degeneration (AMD) in order to restore homeostasis in the retina .
    Risuteganib hydrochloride
  • HY-P1930
    Risuteganib

    		Integrin Inflammation/Immunology
    Risuteganib is a synthetic RGD (arginyl-glycyl-aspartic acid)-class peptide. Risuteganib is an anti-integrin that downregulates oxidative stress and restores homeostasis, and targets three integrin receptors that are implicated in dry age-related macular degeneration (AMD) in order to restore homeostasis in the retina .
    Risuteganib
  • HY-P4320
    Cys-Arg-Gly-Asp-Phe-Pro-Ala-Ser-Ser-Cys (Disulfide bridge: Cys1-Cys10)

    		Integrin Cancer
    Cys-Arg-Gly-Asp-Phe-Pro-Ala-Ser-Ser-Cys (Disulfide bridge: Cys1-Cys10), a decapeptide containing a cyclic RGD active sequence, is an Integrin αIIbβ3 antagonist that inhibits platelet and Adhesion of proMMP-13 .
    Cys-Arg-Gly-Asp-Phe-Pro-Ala-Ser-Ser-Cys (Disulfide bridge: Cys1-Cys10)
  • HY-P1408A
    Obtustatin triacetate

    		Integrin Cancer
    Obtustatin triacetate is a 41-residue non-RGD disintegrin. Obtustatin triacetate can be isolated from the venom of Vipera lebetina obtusa. Obtustatin triacetate is a potent and selective inhibitor of integrin α1β1 adhesion to type IV collagen. Obtustatin triacetate inhibits angiogenesis and may be used in cancer research .
    Obtustatin triacetate
  • HY-P3525
    G-Pen-GRGDSPCA

    		Integrin Others
    G-Pen-GRGDSPCA is an αvβ3-inhibiting RGD peptide. G-Pen-GRGDSPCA can limit neointimal hyperplasia and lumen stenosis after vascular injury, as well as regulate the migration and proliferation of smooth muscle cells. G-Pen-GRGDSPCA can be used in the study of the mechanism of vascular injury repair .
    G-Pen-GRGDSPCA
  • HY-P1189
    Echistatin

    		Integrin Metabolic Disease Inflammation/Immunology
    Echistatin, the smallest active RGD protein belonging to the family of disintegrins that are derived from snake venoms, is a potent inhibitor of platelet aggregation. Echistatin is a potent inhibitor of bone resorption in culture. Echistatin is a potent antagonist of αIIbβ3, αvβ3 and α5β1 .
    Echistatin
  • HY-P1189A
    Echistatin TFA

    		Integrin Metabolic Disease Inflammation/Immunology
    Echistatin TFA, the smallest active RGD protein belonging to the family of disintegrins that are derived from snake venoms, is a potent inhibitor of platelet aggregation. Echistatin is a potent inhibitor of bone resorption in culture. Echistatin is a potent antagonist of αIIbβ3, αvβ3 and α5β1 .
    Echistatin TFA
  • HY-P4896
    FITC-Ahx-Gly-Arg-Gly-Asp-Ser-Pro

    		Integrin Cancer
    FITC-Ahx Gly Arg Gly Asp Ser Pro is a GRGDSP (HY-P0290) coupled to FITC. GRGDSP is an integrin inhibitor that can inhibit the adherence of tumor cells to endothelial cells of blood vessels and limit its metastasis .
    FITC-Ahx-Gly-Arg-Gly-Asp-Ser-Pro
  • HY-126039
    L-739758

    		Integrin Cardiovascular Disease
    L-739758 is an antagonist for αIIbβ3 integrin (platelet glycoprotein IIb/IIIa). L-739758 acts as a peptidomimetic, binds to αIIbβ3 integrin by mimicking the interaction of the RGD (arginine-glycine-aspartic acid) motif, and is involved in the blood coagulation process. L-739758 inhibits platelet aggregation, and is used for thrombosis research .
    L-739758
  • HY-P3448
    Certepetide

    CEND-1; iRGD; LSTA1

    		 Integrin Complement System Cancer
    Certepetide (CEND-1) is a bifunctional cyclic peptide (a.k.a. iRGD). Certepetide is a tumor-penetrating enhancer via RGD motif interaction with alphav-integrins and via activating NRP-1, and transforms the solid tumor microenvironment into a temporary agent conduit. Certepetide accumulates in tumors, and is used in the research of pancreatic cancer and other solid tumors .
    Certepetide
  • HY-P5038
    Cyclo(Gly-Arg-Gly-Asp-Ser-Pro)

    c(GRGDSP)

    		 Integrin Cancer
    Cyclo(Gly-Arg-Gly-Asp-Ser-Pro) (c(GRGDSP)) is an RGD-containing inhibitory peptide. Cyclo(Gly-Arg-Gly-Asp-Ser-Pro) is a synthetic α5β1 integrin ligand that competitively inhibits the binding of invasin (Inv) to α5β1 integrin expressed on Caco-2 cells .
    Cyclo(Gly-Arg-Gly-Asp-Ser-Pro)
  • HY-10220
    SF1126

    		PI3K Apoptosis Cancer
    SF1126 is a relevant pan and dual first-in-class PI3K/BRD4 inhibitor, has antitumor and anti-angiogenic activity. SF1126 is an RGDS-conjugated LY294002 proagent, which is designed to exhibit increased solubility and bind to specific integrins within the tumor compartment. SF1126 induces cell apoptosis .
    SF1126
  • HY-P0178
    LXW7

    		Integrin Inflammation/Immunology
    LXW7, a cyclic peptide containing Arg-Gly-Asp (RGD), is an integrin αvβ3 inhibitor. LXW7 has a high binding affinity to αvβ3 integrin with an IC50 of 0.68 μM. LXW7 increases phosphorylation of VEGFR-2 and activation of ERK1/2. Anti-inflammatory effect .
    LXW7
  • HY-P0178A
    LXW7 TFA

    		Integrin Inflammation/Immunology
    LXW7 TFA, a cyclic peptide containing Arg-Gly-Asp (RGD), is an integrin αvβ3 inhibitor. LXW7 has a high binding affinity to αvβ3 integrin with an IC50 of 0.68 μM. LXW7 TFA increases phosphorylation of VEGFR-2 and activation of ERK1/2. Anti-inflammatory effect .
    LXW7 TFA
  • HY-167686
    Variabilin

    Homopisatin

    		 Integrin Cardiovascular Disease
    Variabilin (Homopisatin) is a potent RGD-containing antagonist of glycoprotein IIb-IIIa and platelet aggregation inhibitor from the hard tick Dermacentor variabilis. Variabilin potently inhibits platelet aggregation induced by the platelet agonists ADP, collagen, and thrombin receptor peptide SFLLRNP. Variabilin also blocks platelet adhesion to immobilized Fg. In addition, Variabilin inhibits binding of purified human GPIIb-IIIa to immobilized Fg .
    Variabilin
  • HY-126402
    Arg-Gly-Asp TFA

    		Integrin Cancer
    Arg-Gly-Asp (RGD) is a synthetic peptide corresponding to the cell adhesion sequence for the integrins αVβ1, αVβ3, αVβ5, αVβ6, αVβ8, α8β1, and α5β1. It is a component of radioligands and peptidomimetics that have been used in the study of integrin expression and activity in vivo.
    Arg-Gly-Asp TFA
  • HY-P2300A
    Cyclo(Arg-Gly-Asp-D-Phe-Cys) TFA
    1 Publications Verification

    Cyclo(RGDfC) TFA

    		 Integrin Cancer
    Cyclo(Arg-Gly-Asp-D-Phe-Cys) (Cyclo RGDfC) TFA, a cyclic RGD peptide which has high affinity to αvβ3, can disrupt cell integrin interactions. Cyclo(Arg-Gly-Asp-D-Phe-Cys) TFA inhibits pluripotent marker expression in embryonic stem cells (ESCs) and the tumorigenic potential of mESCs in vivo. Cyclo(Arg-Gly-Asp-D-Phe-Cys) TFA can be used in the research of tumors .
    Cyclo(Arg-Gly-Asp-D-Phe-Cys) TFA
  • HY-P2300
    Cyclo(Arg-Gly-Asp-D-Phe-Cys)
    1 Publications Verification

    Cyclo(RGDfC)

    		 Integrin Cancer
    Cyclo(Arg-Gly-Asp-D-Phe-Cys) (Cyclo RGDfC), a cyclic RGD peptide which has high affinity to αvβ3, can disrupt cell integrin interactions. Cyclo(Arg-Gly-Asp-D-Phe-Cys) inhibits pluripotent marker expression in embryonic stem cells (ESCs) and the tumorigenic potential of mESCs in vivo. Cyclo(Arg-Gly-Asp-D-Phe-Cys) can be used in the research of tumors .
    Cyclo(Arg-Gly-Asp-D-Phe-Cys)

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: